Lac-Phe Therapy for Ischemic Heart Injury and Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic heart disease, such as drug therapy and PCI, suffer from significant side effects and reperfusion injury risks, necessitating a more effective and safer therapeutic strategy to prevent and treat ischemic heart disease, including coronary heart disease, myocardial infarction, myocardial ischemia-reperfusion injury, myocardial hypertrophy, arrhythmia, and heart failure.
Innovation Solution
Utilizing the endogenous molecule N-lactoyl-phenylalanine (Lac-Phe) to promote angiogenesis, inhibit inflammatory responses, and improve the viability of hypoxic cardiomyocytes, thereby alleviating cardiac injuries associated with ischemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug therapy or PCI is used to treat ischemic heart disease, then therapeutic effect is achieved, but significant side effects and reperfusion injury risks occur
Solution Approach 1:
The patent uses N-lactoyl-phenylalanine (Lac-Phe) as an intermediary substance to mediate the therapeutic effect. Lac-Phe promotes angiogenesis through the CNDP2 enzyme pathway, providing a gentler alternative to conventional drugs and PCI procedures, thereby reducing side effects and reperfusion injury risks while maintaining therapeutic efficacy for ischemic heart disease
Solution Approach 2:
The patent changes the therapeutic parameter from conventional drugs/procedures to an endogenous metabolite (Lac-Phe). By administering Lac-Phe or its precursors (carnosine, phenylalanine), the body naturally produces the therapeutic agent through existing metabolic pathways, particularly in exercise-induced conditions, thereby achieving treatment with reduced harmful effects
2Reliability
If current treatment strategies are applied to prevent secondary myocardial ischemia, then some protection is provided, but adverse drug reactions occur
Solution Approach 1:
The patent leverages the body's own endogenous metabolic pathways to produce the protective agent. Lac-Phe is naturally produced through the action of CNDP2 enzyme on carnosine and phenylalanine, particularly during exercise. By supplementing precursors or directly administering Lac-Phe, the body utilizes its own metabolic machinery to generate protective effects against secondary ischemia without introducing foreign substances that cause adverse reactions
Data Source
AI summary
A use of N-lactoyl-phenylalanine (Lac-Phe) in a preparation of a medicament for preventing and/or treating ischemic heart disease is provided. It is the first to demonstrate that Lac-Phe can improve the cardiac function in a mouse model of left anterior descending coronary artery stenosis, promote cardiac angiogenesis, improve the viability of hypoxic cardiomyocytes, and inhibit the expression of inflammatory cytokines in the heart, thereby playing an anti-myocardial ischemic injury role. Therefore, the Lac-Phe can be used to prepare a medicament for treating ischemic heart disease. A novel technical means for the treatment of ischemic heart disease is provided.